Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2

Sponsor Class

INDUSTRY 1FED 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Neoplasms 2Pain 1Mental Disorders 1Depressive Disorder 1Depression 1Caregiver Burden 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has results × Selective Serotonin Reuptake Inhibitors × Clear all
NCT01077596 2017-05-30

Carcinogenicity Study of Bupropion

GlaxoSmithKline

Completed
50,430 enrolled 23 charts

Depressive Disorder, Neoplasms

NCT00129467 2015-04-24

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

VA Office of Research and Development

Phase NA Completed
47 enrolled 13 charts

Caregiver Burden, Mental Disorders, Depression, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡